It should be noted that ctDNA is increasingly being utilized for tumor response monitoring and identification of minimal residual disease, but in our case we are using a qualitative determination of the BRAF mutation as a first step to detect an early recurrence of the disease, not a quantitative determination that allows us to monitor minimal residual disease or quantify the presence of residual disease [31]. This evidence concerns the gene BRAF and neoplasm.